CD274 and melanoma: High PD-L1 expression prior to anti-PD-1/PD-L1 therapy was later demonstrated to be associated with improved objective response rate and survival in patients with non-small-cell lung cancer [24], melanoma [25] and head and neck squamous cell carcinoma [26].